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Since apoptosis plays an important role in maintaining homeostasis and is associated with responses to therapy, molecular
imaging of apoptotic cells could be useful for early detection of therapeutic effects, particularly in oncology. Radiolabeled annexin
V compounds are the hallmark in apoptosis imaging in vivo. These compounds are reviewed from the genesis of apoptosis
(cell death) imaging agents up to recent years. They have some disadvantages, including slow clearance and immunogenicity,
because they are protein-based imaging agents. For this reason, several studies have been conducted in recent years to
develop low molecule apoptosis imaging agents. In this review, radiolabeled phosphatidylserine targeted peptides, radiolabeled
bis(zinc(II)-dipicolylamine) complex, radiolabeled 5-fluoropentyl-2-methyl-malonic acid (ML-10), caspase-3 activity imaging
agents, radiolabeled duramycin, and radiolabeled phosphonium cation are reviewed as promising low-molecular-weight apoptosis
imaging agents.
1. Introduction
Apoptosis is known to play an important role in maintaining
homeostasis; therefore, it is associated with several diseases
and responses to therapy. Molecular imaging of apoptotic
cells could be useful for elucidation of the diseases and early
detection of therapeutic effects and could contribute to per-
sonalizedmedicine. In this review, we introduce radiolabeled
compounds for molecular imaging of apoptosis (cell death),
their applications, and utility in medicine.
2. Radiolabeled Annexin V
The lipid composition of the outer and inner leaflets of the
plasma membrane is not symmetrical. Phosphatidylserine
(PS) is normally retained on the intracellular face of the cell
membrane. When cells undergo apoptosis, this distribution
is altered, so that PS is rapidly exposed to the outside of
the cell membrane. In fact, not only apoptosis but also some
other forms of cell death including autophagy can externalize
PS [1, 2]. Moreover, in the final stage of almost all forms
of cell death, PS on the intracellular face of the plasma
membrane become accessible to PS-targeting probes in a
nonspecific fashion, because of complete loss of membrane
integrity. Thus, PS-targeted radiolabeled probes must not be
considered specific apoptosis imaging agents, but they may
be used to detect multiple forms of cell death.
In this paper, we have used the phase “apoptosis imaging”
for PS-targeted radiolabeled probes. However, to be accu-
rate, it is “cell death imaging” and not “apoptosis imaging.”
The typical compound of PS targeted carriers is annexin
V, a 36 kDa human protein with a nanomolar affinity for
membrane-bound PS [3–5]. Because of this property, radi-
olabeled annexin V compounds have been developed and
evaluated as in vivo imaging agents for detection of cell death.
3. 99mTc-4,5-bis(thioacetamido)pentanoyl-
Annexin V (99mTc-BTAP-Annexin V)
99mTc is an ideal radionuclide for scintigraphic imaging
applications because of its excellent physical properties,
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low cost, and ready availability as a generator-produced
nuclide. Since most polypeptides do not possess binding
sites allowing them to form 99mTc chelates with high in vivo
stability, appropriate chelating molecules are incorporated
into polypeptide molecules to prepare 99mTc-labeled pep-







coordination molecules, form stable 99mTc
complexes with the [Tc=O]3+ core. In the field of apopto-
sis imaging, 99mTc-4,5-bis(thioacetamido)pentanoyl(BTAP)-
annexin V (Figure 1(a)) was developed as the first 99mTc-





ligand-conjugated annexin V, after development
of iodine-labeled annexin V. The first report of 99mTc-BTAP-
annexinVusewas in thrombosis imaging and not for apopto-
sis imaging. In that paper, Stratton et al. reported that 99mTc-
BTAP-annexin V detected acute left atrial thrombi in vivo in
swine because PS becomes exposed on the surface of activated
platelets [6]. Narula et al. reported that 99mTc-BTAP-annexin
Vwas injected into cardiac allograft recipients. Some patients
who showed at least moderate transplant rejection had pos-
itive myocardial uptake of radioactivity. This study showed
the clinical feasibility of 99mTc-labeled annexin V imaging




ligandsmay require harsh conditions such as high pH or high
temperature to prepare 99mTc complexes with high radio-





ligand was performed using a preformed-chelate
approach. The conjugation between annexin V and 99mTc
complex must be performed after the complexation reaction
of 99mTc. This method requires multiple steps and purifica-
tion, resulting in a 25%–30% overall radiochemical yield. For
routine clinical use, 99mTc labeling of annexin V, which can
be prepared by an easier labeling operation, is required.
4. 99mTc-HYNIC-Annexin V
Blankenberg et al. reported the use of 99mTc-labeled annexin
V, which has hydrazinonicotinamide (HYNIC) as a ligand for
technetium, for apoptosis imaging [8]. HYNIC is one of the
most attractive bifunctional chelating agents for the labeling
of peptides and proteins with 99mTc. It has been reported
that HYNIC acts as a monodentate or bidentate ligand to
form a mixed ligand 99mTc complex in the presence of
appropriate coligands [9]. Tricine has been frequently used as
a coligand since it provides 99mTc-HYNIC-labeled peptides
and proteins with high radiochemical yields and high specific
activities in a short reaction time at room temperature. 99mTc-
HYNIC-annexin V (Figure 1(b)) could be prepared in high
radiochemical yield without any purification after a one-step
reaction. In cultures of Jurkat T-cell lymphoblasts induced
to undergo apoptosis, the uptake of 99mTc-HYNIC-annexin
V directly correlated with the percentage of cells labeled
by FITC-labeled annexin V, which has an affinity for PS
nearly identical to that of the native (unlabeled) protein,
as determined by flow cytometry (𝑟2 = 0.922) [10]. In
another study, the bioactivity of HYNIC-annexin V was
verified by measuring its binding to erythrocyte membranes
containing exposed PS. The affinity of HYNIC-annexin V
was comparable with that of native annexin V. The IC
50
values, which were determined using a competition assay,
were 10.1 ± 2.0 nmol/L and 6.8 ± 0.7 nmol/L, respectively
[11]. Moreover, many studies have demonstrated that 99mTc-
HYNIC-annexin V accumulates in apoptotic cells and can be
used to visualize apoptosis in animal models [12–15]. 99mTc-
HYNIC-annexin V can be considered as a benchmark in the
field of apoptosis imaging, as the easy labeling method has
made this tracer the most extensively investigated and the
best characterized apoptosis-detecting radioligand [16].
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5. Clinical Studies of 99mTc-Labeled Annexin V
in Oncology
For evaluation of the response to cancer therapy, 99mTc-
HYNIC-annexin V imaging should be performed before
and after the starting point of treatment. In a clinical study
reported by Kartachova et al. in 2007, 99mTc-HYNIC-annexin
V imaging in 16 non-small-cell lung cancer patients was
performed before and within 48 hours after the initiation
of platinum-based chemotherapy [17]. All patients, display-
ing imaging data confirming markedly increased uptake of
annexin V in tumor, showed complete or partial response. A
significant correlation (𝑟2 = 0.86; 𝑃 = 0.0001) was found
between the changes of annexin V uptake in tumor and the
treatment outcome.
In another clinical study reported by Rottey et al. in
2006, changes in relative 99mTc-HYNIC-annexin V tumor
uptake in patients undergoing chemotherapy at baseline
and at 5–7 and 40–44 hours after treatment initiation were
investigated [18]. The tumor response was evaluated by
response evaluation criteria in solid tumors (RECIST) and
related to observed changes in the ratios of tumor activity
to background activity. Responders to chemotherapy could
be separated from nonresponders with a 94% accuracy (16/17
patients) by use of the sequential 99mTc-HYNIC-annexin V
imaging and a 25% change threshold.
Although these studies indicated that 99mTc-HYNIC-
annexinV could be a good predictor of the response to cancer
therapy, the numbers of patients in these studies were small.
Furthermore, further larger studies are necessary to confirm
the utility of 99mTc-HYNIC-annexin V for the prediction
of therapeutic effects in early stages after chemotherapy
initiation.
6. Other 99mTc-Labeled Annexin V Compounds
Tait et al. reported the use of 99mTc-labeled annexin V with
site-specific labeling in 2000 [11]. In this study, annexin V
derivatives, containingN-terminal extensions of seven amino
acids for complexation with technetium, were produced














two are predicted to form N
3
S site. The bioactivities of the
mutant proteins were verified by measuring binding activity
to erythrocyte membranes with exposed PS. The mutant
proteins also had the same degree of IC
50
values (9.3 ± 0.4,
10.3±2.5, and 10.0±2.8 nmol/L), which were determined for
unlabeled proteins by competition assay, as HYNIC-annexin
V (10.1±2.0 nmol/L).The radiochemical yields of themutant
proteins with 99mTc were approximately 90%.
Tait et al. reported another annexin V mutant-labeled
with a Tc(I)-carbonyl complex in 2002 [19]. They prepared
annexinVmutants withN-terminal extensions of three or six
histidine residues for labeling with a Tc(I)-tricarbonyl core.
AnnexinV-123, which has anN-terminal extension of six his-
tidine residues, could be superior to annexinV-122, which has
three histidine residues, because 99mTc-labeled annexin V-
123 had higher radiochemical yield and radiochemical purity
and experimentally demonstrated bioactivity in binding to
erythrocytes.










] as a bifunctional
chelating agent to decrease uptake and retention in nontar-
get tissues compared with 99mTc-HYNIC-annexin V [20].





-annexin V showed a much lower kidney accu-
mulation of radioactivity than 99mTc-HYNIC-annexin V.
In the organs for metabolism, such as liver and kidney,
radioactivity after the injection of 99mTc-HYNIC-annexin V
was residual for a long time. On the other hand, radioactivity










-annexin V showed significantly increased tumor
uptake after 5-FU treatment.The accumulation of radioactiv-
ity in tumor correlated positively with the counts of TUNEL-
positive cells.
7. 18F-Labeled Annexin V
Apoptosis imaging probes for positron emission tomography
(PET) are required because PET imaging has high spatial
resolution and great sensitivity, and 18F-labeled annexin V
has been developed. In 2003, Zijlstra et al. reported the
preparation of 18F-labeled annexin V using N-succinimidyl
4-[18F]fluorobenzoate ([18F]SFB) as a labeling reagent [21].
The decay-corrected radiochemical yield was in the range of
15–20%.The 18F-labeled annexinVhighly bound to apoptotic
Jurkat T-cells, compared with nonapoptotic control cells. In
2004, Toretsky et al. also reported 18F-labeled-annexin V
via [18F]SFB [22]. The overall decay-corrected radiochemical
yield of 18F-labeled annexin V from 18F− was comparable
(17.6% ± 5.6%). In addition, Murakami et al. also reported
18F-labeled annexinV by a similar procedure in the same year
[23]. In that study, accumulation of 18F-labeled annexin V in
the infarct area using a rat model of myocardial ischemia and
reperfusionwas comparable to that of 99mTc-labeled-annexin
V with site-specific labeling [11]. However, the complicated
radiosynthesis procedure and the low radiochemical yield
of 18F-labeling (especially, in this study, approximately 10%,
decay-corrected form [18F]SFB) were weak points for clinical
use.
8. 68Ga-Labeled Annexin V
The radionuclide 68Ga has great potential for clinical PET
and could become an attractive alternative to 18F because
of its radiophysical properties, particularly as a generator-
produced nuclide with a half-life (𝑇
1/2
) of 68 minutes [24]. It
does not require an on-site cyclotron and can be eluted on
demand. In principle, the long half-life of the parent nuclide
68Ge (𝑇
1/2
= 270.8 days) provides a generator with a long
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life span. Wangler et al. reported a 68Ga-labeling technique
for proteins using a sulfhydryl-derivatized chelator, 2,2󸀠-(7-
(1-carboxy-4-(2-mercaptoethylamino)-4-oxobutyl)-1,4,7-tri-
azonane-1,4-diyl)diacetic acid (NODA-GA-T) in 2011 [25].
In that study, 68Ga-labeled annexin V was prepared within
a short time of only 15 minutes. In a PET study with an
animal model, the 68Ga-labeled annexin V accumulated in
the apoptotic area by the myocardial infarction.
In the same year, Bauwens et al. reported site-specific
68Ga-labeled annexin V compounds, 68Ga-Dotamaleimide-
conjugated Cys2-annexin V and 68Ga-Dotamaleimide-
conjugated Cys165-annexin V [26]. Cys2-annexin V and
Cys165-annexin V are variants of annexin V containing
a single available cysteine residue at respective positions
2 and 165. Total synthesis time was approximately 55
minutes withan end-of-synthesis yield of 25% (43% if
decay-corrected) in both cases. Both compounds showed
well-preserved PS binding capacity and high in vitro stability
in buffer and in plasma. Tumor uptake of 68Ga-Cys2-annexin
V and 68Ga-Cys165-annexin V was low but significantly
increased after cyclophosphamide and radiation therapy in a
tumor model.
9. Radiolabeled PS Targeted Peptides
Annexin V is best known in the field of apoptosis imaging
as a carrier because it has high affinity for PS and that
radiolabeled annexin V compounds have been extensively
investigated and well characterized. However, the use of
annexin V, a protein, imposes limitations, such as slow
pharmacokinetics and potential immunogenicity. In contrast
to protein-based radioligands like radiolabeled annexin V,
for low-molecular-weight compounds, it is not difficult to
modify chemical structures to improve their biodistribution.
Accordingly, several studies have been performed in recent
years to develop low-molecular-weight apoptosis imaging
agents.
In 1995, Igarashi et al. reported a 14-amino acid synthetic
peptide, FNFRLKAGQKIRFG (PSBP-0), derived from PS
decarboxylase bound to PS effectively and specifically [27].
However, the binding affinity of PSBP-0 was not very high.
In 2011, Xiong et al. modified PSBP-0 to develop peptides
with higher affinity for PS [28]. Each of the 14 residues of
PSBP-0, except the endogenous alanine residue at position
8 (Ala8), was initially replaced with Ala to identify amino
acid residues that contribute to PS affinity. The variant PSBP-
6, in which Gln6 is replaced by Ala, showed the highest
relative binding level and high stability. The binding levels
of PSBP-6 were higher than those of PSBP-0. The remaining
Ala-substituted peptides had lower affinity for PS than the
parent PSBP-0 peptide. Next, Lys[di(2-pryidinemethyl)]-
COOH, termed a single amino acid chelator (SAAC), was
introduced at specific positions of PSBP-0 and PSBP-6 as
a ligand for complexation with technetium. The peptide
containing SAAC introduced at the N-terminus of PSBP-6
(SAAC-PSBP-6, Figure 2(a)) showed greater binding to PS
than PSBP-6. Moreover, the rhenium complex, SAAC(Re)-
PSBP-6 (Figure 2(b)), displayed a higher level of binding than
SAAC-PSBP-6. In a biodistribution study, SAAC(99mTc)-
PSBP-6 (Figure 2(b)) showed significantly higher accumu-
lation in B16/F10 melanoma treated with poly(l-glutamic
acid)-paclitaxel than in untreated tumor (4.1 ± 0.6% ID/g
versus 1.6 ± 0.3% ID/g).
In 2013, Song et al. compared SAAC(99mTc)-PSBP-6 with
[18F]FDG for detecting apoptosis induced by chemotherapy
[29]. In B16/F10 melanoma and 38C13 lymphoma tumor
models, the uptake of SAAC(99mTc)-PSBP-6 significantly
increased on the first day after treatment, whereas [18F]FDG
uptake significantly decreased. The uptake of SAAC(99mTc)-
PSBP-6 negatively correlated with that of [18F]FDG (𝑟 =
−0.79, 𝑃 < 0.05). These results indicated that the
SAAC(99mTc)-PSBP-6 could be a useful probe to evaluate
early therapeutic response after chemotherapy.
10. Bis(zinc(II)-dipicolylamine) Complex
Binuclear Zn(II) complexes of 2,2󸀠-dipicolylamine (Zn2+-
DPA) are known as an effective binding motif for phosphate
anion [30]. Because PS is an anionic phospholipid, Zn2+-
DPA has a selective affinity for biomembranes enriched
with PS and could have an apoptosis sensing function. In
2011, Wyffels et al. reported 99mTc labeled Zn2+-DPA with a
99mTc-tricarbonyl core and via 99mTc-HYNIC (Figures 3(a)
and 3(b)) [31]. Both compounds showed significantly higher
uptake in livers of anti-Fas antibody-treated mice compared
with that in livers of control mice. The increased liver uptake
of 99mTc-labeled Zn2+-DPAwas comparable to that of 99mTc-
labeled annexin V, indicating the in vivo affinity of 99mTc
labeled Zn2+-DPA for hepatic apoptosis.
Recently, Wang et al. reported the 18F-labeled Zn2+-DPA
compounds, 2-18F-fluoroethyl-bis(zinc(II)-dipicolylamine)
(18F-FEN-DPAZn2) and 4-18F-fluoro-benzoyl-bis(zinc(II)-
dipicolylamine) (18F-FB-DPAZn2) (Figures 3(c) and 3(d)),
as apoptosis (cell death) imaging agents [32]. Decay-
uncorrected radiochemical yields of the precursors of
18F-FEN-DPAZn2 and 18F-FB-DPAZn2, 18F-FEN-DPA2 and
18F-FB-DPA2, were 8.9% and 13%, respectively. 18F-FEN-
DPAZn2 and 18F-FB-DPAZn2 complexes were prepared





authors described that the low radiochemical yield of 18F-
FEN-DPA2 limited further animal experiments. In vivo PET
imaging experiments using 18F-FDG, 18F-FB-DPA2, and
18F-FB-DPAZn2 were performed in Hepa1-6 hepatocellular
carcinoma-bearing mice and adriamycin-treated tumor-
bearing mice. 18F-FDG and 18F-FB-DPA2 showed no
significant uptake change before and after chemotherapy.
These results indicate that 18F-FDG could lack specificity
to monitor anticancer therapy and that 18F-FB-DPA2 has
no binding affinity to PS without zinc. In contrast, 18F-
FB-DPAZn2 showed significantly higher accumulation in
adriamycin-treated tumors compared with that in untreated
ones. However, the background uptake of 18F-FB-DPAZn2
in liver and intestine was high. Optimization of the chemical

















M = Re, 99mTc
Phe–Asn–Phe–Arg–Leu–Lys–Ala–Gly–Ala–Lys–lle–Arg–Phe–Gly–NH2
(b)
Figure 2: Structures of (a) SAAC-PSBP-6 and (b) SAAC(Re)-PSBP-6 and SAAC(99mTc)-PSBP-6.
structure is needed to improve its biodistribution to obtain
images with higher signal/noise (𝑆/𝑁) ratio.
11. 18F-Labeled 5-Fluoropentyl-2-methyl-
malonic Acid (18F-ML-10)
Several physiologically relevant processes, such as apopto-
sis, platelet activation, neurotransmitter release, and sperm
capacitation, require dissipation of plasma membrane lipid
asymmetry, a process known as scrambling. Apoptosis-
related PS exposure on the cell surface is a classic feature
of apoptotic cells and acts as an “eat me” signal allowing
phagocytosis of postapoptotic bodies [33].
A family of small molecules, ApoSense, rationally
designed to detect apoptosis-related complexes of cellular
alterations, with consequent selective accumulation within
apoptotic cells driven by the apoptotic scramblase activa-
tion, depolarization, and cellular acidification, have been
reported as compounds capable of discriminating between
vital and apoptotic cells [34]. In the ApoSense family, 18F-
labeled 5-fluoropentyl-2-methyl-malonic acid (18F-ML-10,
Figure 4(a)) was reported by Reshef et al. as a PET tracer
of cell death in 2008 [35]. 18F-ML-10 showed fast blood
clearance and little accumulation in normal tissues and rapid
elimination via kidneys. Stability of 18F-ML-10 was very high
and no metabolite was observed in blood and the brain. The
absence of accumulation in bone indicated that defluorina-
tion of 18F-ML-10 did not occur. In an experimental acute
cerebral stroke mouse model, 18F-ML-10 was retained in the
stroke area but was cleared from intact brain areas. In 2011,
a favorable dosimetry and safety profile of 18F-ML-10 were
demonstrated in first human study [36]. Binding to apoptotic
sites was also demonstrated.
The molecular design of 18F-ML-10 comprised the fol-
lowing steps: (1) attachment of an alkyl chain to render the
molecule amphipathic for membrane interaction, (2) opti-
mization of the alkyl-chain length, based on pharmacokinetic
considerations, (3) addition of a methyl group at the 𝛼-
position to prevent metabolism in vivo, and (4) attachment
of a fluorine atom for PET imaging with 18F. To identify the
mechanism of action, Cohen et al. synthesized and evaluated
3H-ML-10 [37]. The uptake of 3H-ML-10 in apoptotic cells
occurred in parallel to annexin V binding. Approximately 10-
fold higher accumulation of 3H-ML-10 was observed in anti-
Fas antibody-treated apoptotic Jurkat cells compared with
































































Figure 3: Structures of (a) 99mTc-labeled Zn2+-DPA with 99mTc-tricarbonyl core, (b) 99mTc-labeled Zn2+-DPA with 99mTc-HYNIC, (c) 18F-











Figure 4: Structures of (a) 18F-ML-10 and (b) 123I-ML-10.
that in untreated control cells. 3H-ML-10 crossed the cell
membrane at the stage of early apoptosis and was mainly
localized in the cytoplasm (60%) and in the nucleus (30%).
Interestingly, 3H-ML-10 accumulated only in apoptotic cells
and not in either untreated control cells or necrotic cells
induced by freeze-thaw injury.
Recently, 123I-labeled ML-10 analog as a single photon
emission tomography (SPECT) tracer was reported.
[123I]-2-(5-iodopentyl)-2-methylmalonic acid (123I-ML10,
Figure 4(b)) was expected to show increased penetration in
apoptotic cells because of its greater lipophilicity compared
with 18F-ML-10 [38]. 123I-ML10 accumulated in apoptotic
cells, but a clear uptake in the thyroid, resulting from in vivo
deiodination, was observed because of its instability.
12. Caspase-3 Activity Imaging Agents
The caspases are a family of intracellular cysteine aspartate-
specific proteases that play an important role in the initiation
and execution of apoptosis [39]. Caspases are subdivided
into three groups on the basis of homology and substrate
specificity: (1) caspases involved in inflammation (caspases 1,
4, 5, and 13); (2) initiator caspases which are found at the top




































Figure 5: Structures of (a) Isatin, (b) (S)-1-benzyl-5-[1-[2-(phenoxymethyl)pyrrolidinyl]sulfonyl]isatin, (c) WC-II-89, and (d) [18F]ICMT-11.
of the signaling cascade (caspases 6 and 8–10), and (3) effector
caspases which are activated further downstream (caspases 2,
3, and 7) [40]. Among these caspases, caspase-3 is a frequently
activated death protease, catalyzing the specific cleavage of
many key cellular proteins [41]. Thus, caspase-3 should be an
attractive biomarker for apoptosis.
In 2001, Lee et al. determined the activity and the
selectivity of a series of isatin (Figure 5(a)) analogs for
caspase-3 [42]. They found that the substituent at position
5 was important and demonstrated a correlation between
the electron-withdrawing ability of the substituent at
position 5 and the potency of caspase-3 inhibition. The
5-dialkylaminosulfonylisatins were identified as potent
inhibitors of caspases 3 and 7. Within this series, (S)-1-
benzyl-5-[1-[2-(phenoxymethyl)pyrrolidinyl]sulfonyl]isatin
(Figure 5(b)) was the most promising and showed very high
activity and selectivity for caspases 3 and 7.
In 2006, Zhou et al. synthesized WC-II-89 (Figure 5(c)),
an isatin sulfonamide analog containing a fluorine atom that
has a structure similar to that of compound 5B [43].WC-II-89
was a highly potent inhibitor of caspases 3 and 7 anddisplayed
high selectivity with respect to other caspases. [18F]WC-II-
89 was prepared via a nucleophilic substitution of the corre-
sponding mesylate precursor with [18F]fluoride ion in high
radiochemical yield. In animal experiments, [18F]WC-II-89
showed higher uptake in the liver of a cycloheximide-treated
rat, a model for chemically induced apoptosis, compared to
the untreated control. Western blot analysis confirmed that
the uptake was related to caspase-3 activation.
In 2008, Smith et al. reported the synthesis and char-
acterization of the 18F-labeled isatin analog (S)-1-[[1-(2-
fluoroethyl)-1H-[1,2,3]triazol-4-yl]methyl]-5-[2-(2,4- difluo-
rophenoxy)methyl-pyrrolidine-1-sulfonyl]isatin ([18F]ICMT-
11, Figure 5(d)). [18F]ICMT-11 possesses the characteristic
of high metabolic stability with no indication of defluo-
rination in vivo, reduced lipophilicity, and subnanomolar
affinity for caspase-3 [44]. “Click labeling” provided [18F]
ICMT-11 in 65% decay-corrected radiochemical yield from 2-
[18F]fluoroethylazide.
In 2009, Nguyen et al. reported the results of a detailed
in vitro study and an animal PET study of [18F]ICMT-11
[45]. In vitro binding of [18F]ICMT-11 was increased in drug-
treated cells and corresponded to higher cellular activity of
caspases 3 and 7. In addition, [18F]ICMT-11 binding did not
increase in caspase-3 deficient MCF-7 human breast cancer
cells treated with 4-hydroperoxycyclophosphamide (4-HC),
compared with a control. In the PET study, the [18F]ICMT-
11 signal increased in up to twofold during the first 24 hours
after treatment. Other papers have also recently indicated
that [18F]ICMT-11 could be useful as a caspase-3 imaging
apoptosis tracer [46, 47].
In 2013, Challapalli et al. reported the result of a PET
study in healthy human volunteers that revealed the biodis-
tribution and internal dosimetry profiles of [18F]ICMT-11
[48]. [18F]ICMT-11 was shown to be a safe PET tracer with a
favorable radiation dosimetry profile for clinical use. Further
clinical studies of [18F]ICMT-11 for apoptosis imaging are
anticipated.
13. Radiolabeled Duramycin
Phosphatidylethanolamine (PE) is the second most abun-
dant phospholipid and accounts for approximately 20% of
all phospholipids in mammalian cellular membranes [49].
Similar to PS, PE is a major component of the inner leaflet of








































Figure 6: Structure of duramycin.
the cell membrane and is rare on the surface of normal viable
cells [50]. When apoptosis occurs, PE is exposed onto the
cell surface [51]. Thus, PE could also be a target molecule for
apoptosis imaging. As a potential molecular probe candidate
for PE, duramycin (2 kDa), which is produced by Streptover-
ticillium cinnamoneus, is a tetracyclic peptide consisting of 19
amino acids (Figure 6) [52, 53] and binds the head group of
PE with high affinity (𝐾
𝑑
= 11 nM) at a molar ratio of 1 : 1 [54–
56].
In 2008, Zhao et al. reported 99mTc-labeled duramycin,
which is a novel PE-bindingmolecular probe, using aHYNIC
ligand with tricine and phosphine as coligands [57]. In a
myocardial ischemia/reperfusion injury lesion using a rat
model, 99mTc-duramycin showed specific higher uptake in
apoptotic cells compared with that in viable control cells.
Intravenously injected 99mTc-duramycin showed favorable
pharmacokinetic and biodistribution profiles. It was rapidly
cleared from the circulation via the renal system with a
blood half-life of less than 4 minutes in rats. Hepatic and
gastrointestinal uptake was very low. In addition, 99mTc-
duramycin was evaluated for ischemia/reperfusion injury in
brain using the rat model of middle cerebral artery occlusion
(MCAO) [58], oxidative lung injury [59], and damage in
susceptible tissues after high-dose radiation exposure [60]. In
all cases, 99mTc-duramycin could detect apoptotic cells and
was useful for the estimation of the degree of the symptoms.
Recently, Yao et al. reported 18F-labeled duramycin,
[18F]FPDuramycin, as a novel tracer for PET imaging of
cell death [61]. [18F]FPDuramycin was successful in visu-
alizing tumor cell death after treatment with cyclophos-
phamide and cisplatin in tumor-bearing mice using PET.
However, its pharmacokinetics was not favorable because
[18F]FPDuramycin showed high accumulation in the liver




It is known that mitochondria play an important role in
an intrinsic pathway of apoptosis. Disruption of the mito-
chondrial membrane potential (ΔΨm) and mitochondrial
outer membrane permeabilization, which leads to the release
P+ F
Figure 7: Structure of [18F]-p-fluorobenzyl triphenylphosphonium
cation (18F-FBnTP).
of intermembrane proteins including cytochrome c and
others, occurs at an early stage of apoptosis [62, 63]. The
collapse of ΔΨm occurs before the major morphology and
biochemistry changes of apoptosis including nuclear DNA
fragmentation and externalization of membranous PS [63].
Moreover, although the transient exposure of the PS allows
measurement of the extent of the apoptosis during a limited
time window, the loss of ΔΨm is an ongoing process not
limited to a time window. Thus, monitoring ΔΨm could offer
the information about the kinetics of the apoptotic process
in the target tissue and could accordingly be an effective
approach for detecting apoptosis at an early stage.
Phosphonium cations can pass through the lipid bilayer
because they are sufficiently lipophilic and their positive
charge is delocalized. In addition, because the membrane
potential of mitochondria is the highest in cells, phospho-
nium cations could selectively accumulate in the innerior of
the mitochondria [64]. Consequently, when apoptosis causes
loss of ΔΨm, phosphonium cations in cells would decrease.
In 2007, Madar et al. reported the 18F-labeled phospho-
nium cation, 18F-fluorobenzyl triphenylphosphonium cation
(18F-FBnTP, Figure 7), as a PET tracer for noninvasive
assessment of ΔΨm [65]. The performance of
18F-FBnTP for
measuring changes in membrane potential was comparable
to that of 3H-tetraphenylphosphonium (3H-TPP), which
has been used for measurement of ΔΨm in vitro. In vitro
experiments assessing the dependence of 18F-FBnTP uptake
on membrane potential showed that about 80% of total
uptake was ΔΨm-dependent, about 10% was plasma mem-
brane potential (ΔΨp)-dependent, and remaining about 10%
was independent ofmembrane potential, namely, nonspecific
binding. Therefore, the change of radioactivity accumulation
in the target tissue determined using 18F-FBnTPPET imaging
could mainly reflect changes in ΔΨm.
In 2009, Madar et al. reported in vivo study of 18F-
FBnTP [66]. Tumor uptake under anticancer treatment was
evaluated in orthotropic prostate tumor-bearing mice. At 48
hours after treatment with docetaxel, 18F-FBnTP and 18F-
FDG were intravenously administered. At 60 minutes after
injection, 18F-FBnTP uptake (percentage of dose per gram)
in the prostate tumor of untreated mice was 1.84 ± 0.65 and
that of treated mice was 0.90 ± 0.31. In contrast, 18F-FDG
uptake levels in the prostate tumors of untreated mice and
of treated mice were 1.31 ± 0.14 and 1.15 ± 0.54, respectively.
Treatment with docetaxel resulted in a significant decline in
tumor uptake of 18F-FBnTP (54.2%), but 18F-FDG showed
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no significant change in tumor uptake on treatment with
docetaxel. Thus, the measurement of ΔΨm using
18F-FBnTP
could be an effective strategy for the early detection of
apoptosis.
15. Summary
In this review, we introduced a variety of apoptosis imaging
probes. The most typical probes were radiolabeled agents
that bind to PS, such as radiolabeled annexin V. Studies in
model systems as well as clinical studies have demonstrated
that the accumulation of PS-directed probes correlates with
apoptotic cells after therapy. However, PS-directed probes
accumulate not only as a result of apoptosis but also as a result
of other forms of cell death. Both PS and PE are exposed onto
the cell surface during apoptosis. PE-directed probes, such
as radiolabeled duramycin, could also be apoptosis imaging
agents using the same strategy used with PS-directed probes.
Unlike PS- or PE-directed probes, caspase-3 imaging probes
were expected to specifically detect apoptosis. Promising
caspase-3 imaging probes have been developed, and their
accumulation in apoptosis in animal models was shown to be
higher than that in controls. However, the specificity of the
imaging probe [18F]ICMT-11, which targets caspases 3 and
7, for the detection of apoptotic cells was not shown [45].
The small-molecule 18F-ML-10 (MW 206) is an apoptosis
probe for PET that has simple structure derived from the
ApoSense family. Although 18F-ML-10 binds at apoptotic
sites, the absolute uptake of 18F-ML-10 in apoptotic tissue
could be not enough. The probe 18F-FBnTP, which is used to
assess ΔΨm, can detect apoptosis because disruption of ΔΨm
occurs at an early stage of apoptosis. The loss of ΔΨm is not
limited to a specific time window, unlike the transient nature
of PS exposure. A disadvantage of probes that assess ΔΨm
is that their uptake may display a negative correlation with
apoptosis.
Quantitative imaging of apoptosis (cell death) provides
useful information for therapeutic effects on diseases before
anatomical changes of the lesion site. Selection of the appro-
priate therapies on the basis of the imaging data from the
patients may be possible. Because the apoptosis imaging
can allow evaluating the therapeutic effects of drugs under
development, this modality may help the screening of novel
compounds. Some promising agents have been developed in
recent years as we introduced some of them in the review, but
their imaging quality is not always sufficient. We hope that
novel apoptosis imaging agents, showing higher 𝑆/𝑁 ratios,
will be developed in the near future.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
References
[1] M. Verheij, “Clinical biomarkers and imaging for radiotherapy-
induced cell death,” Cancer and Metastasis Reviews, vol. 27, no.
3, pp. 471–480, 2008.
[2] G. Melino, R. A. Knight, and P. Nicotera, “How many ways to
die? How many different models of cell death?” Cell Death &
Differentiation, vol. 12, no. 2, pp. 1457–1462, 2005.
[3] P. W. Vriens, F. G. Blankenberg, J. H. Stoot et al., “The use of
technetium Tc 99m annexin V for in vivo imaging of apoptosis
during cardiac allograft rejection,” Journal of Thoracic and
Cardiovascular Surgery, vol. 116, no. 5, pp. 844–853, 1998.
[4] J. F. Tait, D. Gibson, and K. Fujikawa, “Phospholipid binding
properties of human placental anticoagulant protein-I, a mem-
ber of the lipocortin family,”The Journal of Biological Chemistry,
vol. 264, no. 14, pp. 7944–7949, 1989.
[5] J. H. Walker, C. M. Boustead, J. J. Koster, M. Bewley, and
D. A. Waller, “Annexin V, a calcium-dependent phospholipid-
binding protein,” Biochemical Society Transactions, vol. 20, no.
4, pp. 828–833, 1992.
[6] J. R. Stratton, T. A. Dewhurst, S. Kasina et al., “Selective uptake
of radiolabeled annexin V on acute porcine left atrial thrombi,”
Circulation, vol. 92, no. 10, pp. 3113–3121, 1995.
[7] J. Narula, E. R. Acio, N. Narula et al., “Annexin-V imaging
for noninvasive detection of cardiac allograft rejection,” Nature
Medicine, vol. 7, no. 12, pp. 1347–1352, 2001.
[8] F. G. Blankenberg, P. D. Katsikis, J. F. Tait et al., “In vivo
detection and imaging of phosphatidylserine expression during
programmed cell death,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 95, no. 11, pp. 6349–
6354, 1998.
[9] R. C. King, M. B.-U. Surfraz, S. C. G. Biagini, P. J. Blower,
and S. J. Mather, “How do HYNIC-conjugated peptides bind
technetium? Insights from LC-MS and stability studies,”Dalton
Transactions, no. 43, pp. 4998–5007, 2007.
[10] F. G. Blankenberg, P. D. Katsikis, J. F. Tait et al., “Imaging
of apoptosis (programmed cell death) with 99𝑚Tc annexin V,”
Journal of Nuclear Medicine, vol. 40, no. 1, pp. 184–191, 1999.
[11] J. F. Tait, D. S. Brown, D. F. Gibson, F. G. Blankenberg, and H.
W. Strauss, “Development and characterization of annexin V
mutants with endogenous chelation sites for 99𝑚Tc,” Bioconju-
gate Chemistry, vol. 11, no. 6, pp. 918–925, 2000.
[12] T.Doue, K.Ohtsuki, K.Ogawa et al., “Cardioprotective effects of
erythropoietin in rats subjected to ischemia-reperfusion injury:
Assessment of infarct size with 99𝑚Tc- annexin V,” Journal of
Nuclear Medicine, vol. 49, no. 10, pp. 1694–1700, 2008.
[13] T. Takei, Y. Kuge, S. Zhao et al., “Time course of apoptotic tumor
response after a single dose of chemotherapy: comparison
with 99𝑚Tc-annexin V uptake and histologic findings in an
experimental model,” Journal of Nuclear Medicine, vol. 45, no.
12, pp. 2083–2087, 2004.
[14] K. Ohtsuki, K. Akashi, Y. Aoka et al., “Technetium-99m
HYNIC-annexin V: a potential radiopharmaceutical for the
in-vivo detection of apoptosis,” European Journal of Nuclear
Medicine, vol. 26, no. 10, pp. 1251–1258, 1999.
[15] M.-F. Guo, Y. Zhao, R. Tian et al., “In vivo 99𝑚Tc-HYNIC-
annexin V imaging of early tumor apoptosis in mice after single
dose irradiation.,” Journal of experimental & clinical cancer
research, vol. 28, article 136, 2009.
[16] F. G. Blankenberg, J.-L. Vanderheyden, H. W. Strauss, and J.
F. Tait, “Radiolabeling of HYNIC-annexin V with technetium-
99m for in vivo imaging of apoptosis,” Nature Protocols, vol. 1,
no. 1, pp. 108–110, 2006.
[17] M. Kartachova, N. van Zandwijk, S. Burgers, H. van Tinteren,
M. Verheij, and R. A. V. Olmos, “Prognostic significance of
99𝑚TcHynic-rh-annexin V scintigraphy during platinum-based
10 The Scientific World Journal
chemotherapy in advanced lung cancer,” Journal of Clinical
Oncology, vol. 25, no. 18, pp. 2534–2539, 2007.
[18] S. Rottey, G. Slegers, S. van Belle, I. Goethals, and C. van
deWiele, “Sequential 99𝑚Tc-hydrazinonicotinamide-annexin V
imaging for predicting response to chemotherapy,” Journal of
Nuclear Medicine, vol. 47, no. 11, pp. 1813–1818, 2006.
[19] J. F. Tait, C. Smith, and D. F. Gibson, “Development of annexin
V mutants suitable for labeling with Tc(I)-carbonyl complex,”
Bioconjugate Chemistry, vol. 13, no. 5, pp. 1119–1123, 2002.
[20] K. Ogawa, K. Ohtsuki, T. Shibata et al., “Development and
evaluation of a novel 99𝑚Tc-labeled annexin A5 for early
detection of response to chemotherapy,” PLoS ONE, vol. 8, no.
12, Article ID e81191, 2013.
[21] S. Zijlstra, J. Gunawan, and W. Burchert, “Synthesis and eval-
uation of a 18F-labelled recombinant annexin-V derivative, for
identification and quantification of apoptotic cells with PET,”
Applied Radiation and Isotopes, vol. 58, no. 2, pp. 201–207, 2003.
[22] J. Toretsky, A. Levenson, I. N. Weinberg, J. F. Tait, A. U¨ren,
and R. C. Mease, “Preparation of F-18 labeled annexin V: a
potential PET radiopharmaceutical for imaging cell death,”
Nuclear Medicine and Biology, vol. 31, no. 6, pp. 747–752, 2004.
[23] Y.Murakami, H. Takamatsu, J. Taki et al., “ 18F-labelled annexin
V: a PET tracer for apoptosis imaging,” European Journal of
NuclearMedicine andMolecular Imaging, vol. 31, no. 4, pp. 469–
474, 2004.
[24] K. P. Zhernosekov, D. V. Filosofov, R. P. Baum et al., “Processing
of generator-produced 68Ga for medical application,” Journal of
Nuclear Medicine, vol. 48, no. 10, pp. 1741–1748, 2007.
[25] C. Wangler, B. Wangler, S. Lehner et al., “A universally appli-
cable 68Ga-labeling technique for proteins,” Journal of Nuclear
Medicine, vol. 52, no. 4, pp. 586–591, 2011.
[26] M. Bauwens, M. de Saint-Hubert, E. Devos et al., “Site-specific
68Ga-labeledAnnexinA5 as a PET imaging agent for apoptosis,”
Nuclear Medicine and Biology, vol. 38, no. 3, pp. 381–392, 2011.
[27] K. Igarashi, M. Kaneda, A. Yamaji et al., “A novel
phosphatidylserine-binding peptide motif defined by an
anti-idiotypic monoclonal antibody. Localization of phos-
phatidylserine-specific binding sites on protein kinase C
and phosphatidylserine decarboxylase,” Journal of Biological
Chemistry, vol. 270, no. 49, pp. 29075–29078, 1995.
[28] C. Xiong, K. Brewer, S. Song et al., “Peptide-based imaging
agents targeting phosphatidylserine for the detection of apopto-
sis,” Journal ofMedicinal Chemistry, vol. 54, no. 6, pp. 1825–1835,
2011.
[29] S. Song, C. Xiong,W. Lu, G. Ku, G.Huang, andC. Li, “Apoptosis
imaging probe predicts early chemotherapy response in preclin-
ical models: a comparative study with 18F-FDG PET,” Journal of
Nuclear Medicine, vol. 54, no. 1, pp. 104–110, 2013.
[30] T. Sakamoto, A. Ojida, and I. Hamachi, “Molecular recognition,
fluorescence sensing, and biological assay of phosphate anion
derivatives using artificial Zn(II)-Dpa complexes,” Chemical
Communications, no. 2, pp. 141–152, 2009.
[31] L. Wyffels, B. D. Gray, C. Barber, J. M. Woolfenden, K. Y. Pak,
and Z. Liu, “Synthesis and preliminary evaluation of radiola-
beled bis(zinc(II)- dipicolylamine) coordination complexes as
cell death imaging agents,” Bioorganic & Medicinal Chemistry,
vol. 19, no. 11, pp. 3425–3433, 2011.
[32] H. Wang, X. Tang, G. Tang et al., “Noninvasive positron
emission tomography imaging of cell death using a novel
small-molecule probe, 18F labeled bis(zinc(II)-dipicolylamine)
complex,” Apoptosis, vol. 18, no. 8, pp. 1017–1027, 2013.
[33] G. Marino and G. Kroemer, “Mechanisms of apoptotic phos-
phatidylserine exposure,” Cell Research, vol. 23, no. 11, pp. 1247–
1248, 2013.
[34] M. Damianovich, I. Ziv, S. N. Heyman et al., “ApoSense: a novel
technology for functional molecular imaging of cell death in
models of acute renal tubular necrosis,” European Journal of
Nuclear Medicine and Molecular Imaging, vol. 33, no. 3, pp. 281–
291, 2006.
[35] A. Reshef, A. Shirvan, R. N. Waterhouse et al., “Molecular
imaging of neurovascular cell death in experimental cerebral
stroke by PET,” Journal of Nuclear Medicine, vol. 49, no. 9, pp.
1520–1528, 2008.
[36] J. Ho¨glund, A. Shirvan, G. Antoni et al., “ 18F-ML-10, a PET
tracer for apoptosis: first human study,” Journal of Nuclear
Medicine, vol. 52, no. 5, pp. 720–725, 2011.
[37] A. Cohen, A. Shirvan, G. Levin, H. Grimberg, A. Reshef, and I.
Ziv, “From the gla domain to a novel small-molecule detector
of apoptosis,” Cell Research, vol. 19, no. 5, pp. 625–637, 2009.
[38] M. Bauwens, M. de Saint-Hubert, J. Cleynhens et al., “In vitro
and in vivo comparison of 18F and 123I- labeledML10with 68Ga-
Cys2-AnxA5 for molecular imaging of apoptosis,” Quarterly
Journal of Nuclear Medicine and Molecular Imaging, vol. 57, no.
2, pp. 187–200, 2013.
[39] J. Li and J. Yuan, “Caspases in apoptosis and beyond,”Oncogene,
vol. 27, no. 48, pp. 6194–6206, 2008.
[40] D. W. Nicholson and N. A. Thornberry, “Caspases: killer
proteases,” Trends in Biochemical Sciences, vol. 22, no. 8, pp.
299–306, 1997.
[41] A. G. Porter and R. U. Ja¨nicke, “Emerging roles of caspase-3 in
apoptosis,”Cell Death&Differentiation, vol. 6, no. 2, pp. 99–104,
1999.
[42] D. Lee, S. A. Long, J. H. Murray et al., “Potent and selective
nonpeptide inhibitors of caspases 3 and 7,” Journal of Medicinal
Chemistry, vol. 44, no. 12, pp. 2015–2026, 2001.
[43] D. Zhou, W. Chu, J. Rothfuss et al., “Synthesis, radiolabeling,
and in vivo evaluation of an 18F-labeled isatin analog for
imaging caspase-3 activation in apoptosis,” Bioorganic and
Medicinal Chemistry Letters, vol. 16, no. 19, pp. 5041–5046, 2006.
[44] G. Smith, M. Glaser, M. Perumal et al., “Design, synthe-
sis, and biological characterization of a caspase 3/7 selective
isatin labeled with 2-[18f]fluoroethylazide,” Journal of Medicinal
Chemistry, vol. 51, no. 24, pp. 8057–8067, 2008.
[45] Q.-D. Nguyen, G. Smith, M. Glaser, M. Perumal, E. A˚rstad,
and E. O. Aboagye, “Positron emission tomography imaging
of drug-induced tumor apoptosis with a caspase-3/7 specific
[18F]-labeled isatin sulfonamide,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 106, no.
38, pp. 16375–16380, 2009.
[46] Q.-D. Nguyen, I. Lavdas, J. Gubbins et al., “Temporal and
spatial evolution of therapy-induced tumor apoptosis detected
by caspase-3-selective molecular imaging,” Clinical Cancer
Research, vol. 19, no. 14, pp. 3914–3924, 2013.
[47] T. H. Witney, R. R. Fortt, and E. O. Aboagye, “Preclinical
assessment of carboplatin treatment efficacy in lung cancer by
18F-ICMT-11-positron emission tomography,” PLoS ONE, vol. 9,
no. 3, Article ID e91694, 2014.
[48] A. Challapalli, L. M. Kenny,W. A. Hallett et al., “ 18F-ICMT-11, a
caspase-3-specific PET tracer for apoptosis: biodistribution and
radiation dosimetry,” Journal of Nuclear Medicine, vol. 54, no. 9,
pp. 1551–1556, 2013.
The Scientific World Journal 11
[49] A. A. Spector and M. A. Yorek, “Membrane lipid composition
and cellular function,” Journal of Lipid Research, vol. 26, no. 9,
pp. 1015–1035, 1985.
[50] E. M. Bevers, P. Comfurius, D. W. C. Dekkers, and R. F. A.
Zwaal, “Lipid translocation across the plasma membrane of
mammalian cells,” Biochimica et Biophysica Acta: Molecular and
Cell Biology of Lipids, vol. 1439, no. 3, pp. 317–330, 1999.
[51] K. Emoto, N. Toyama-Sorimachi, H. Karasuyama, K. Inoue,
andM. Umeda, “Exposure of phosphatidylethanolamine on the
surface of apoptotic cells,” Experimental Cell Research, vol. 232,
no. 2, pp. 430–434, 1997.
[52] F. Hayashi, K. Nagashima, Y. Terui, Y. Kawamura, K. Mat-
sumoto, and H. Itazaki, “The structure of PA48009: the revised
structure of duramycin,” Journal of Antibiotics, vol. 43, no. 11, pp.
1421–1430, 1990.
[53] N. Zimmermann, S. Freund, A. Fredenhagen, and G. Jung,
“Solution structures of the lantibiotics duramycin B and C,”
European Journal of Biochemistry, vol. 216, no. 2, pp. 419–428,
1993.
[54] F.Ma¨rki, E. Ha¨nni, A. Fredenhagen, and J. vanOostrum, “Mode
of action of the lanthionine-containing peptide antibiotics
duramycin, duramycin B and C, and cinnamycin as indirect
inhibitors of phospholipaseA2,”Biochemical Pharmacology, vol.
42, no. 10, pp. 2027–2035, 1991.
[55] K. Iwamoto, T. Hayakawa, M. Murate et al., “Curvature-
dependent recognition of ethanolamine phospholipids by
duramycin and cinnamycin,” Biophysical Journal, vol. 93, no. 5,
pp. 1608–1619, 2007.
[56] J. Seelig, “Thermodynamics of lipid-peptide interactions,”
Biochimica et Biophysica Acta—Biomembranes, vol. 1666, no. 1-
2, pp. 40–50, 2004.
[57] M. Zhao, Z. Li, and S. Bugenhagen, “ 99𝑚Tc-labeled duramycin
as a novel phosphatidylethanolamine-binding molecular
probe,” Journal of Nuclear Medicine, vol. 49, no. 8, pp. 1345–
1352, 2008.
[58] Y. Zhang, G. D. Stevenson, C. Barber et al., “Imaging of
rat cerebral ischemia-reperfusion injury using 99𝑚Tc-labeled
duramycin,”NuclearMedicine and Biology, vol. 40, no. 1, pp. 80–
88, 2013.
[59] A. V. Clough, S. H. Audi, S. T. Haworth, and D. L. Roerig,
“Differential lung uptake of 99𝑚Tc-hexamethylpropyleneamine
oxime and 99𝑚Tc-duramycin in the chronic hyperoxia rat
model,” Journal of Nuclear Medicine, vol. 53, no. 12, pp. 1984–
1991, 2012.
[60] S. E. Johnson, Z. Li, Y. Liu, J. E. Moulder, andM. Zhao, “Whole-
body imaging of high-dose ionizing irradiation—induced tissue
injuries using 99𝑚Tc-duramycin,” Journal of Nuclear Medicine,
vol. 54, no. 8, pp. 1397–1403, 2013.
[61] S. Yao, K. Hu, G. Tang et al., “Positron emission tomography
imaging of cell death with [18F]FPDuramycin,” Apoptosis, vol.
19, no. 5, pp. 841–850, 2014.
[62] D. R. Green and G. Kroemer, “The pathophysiology of mito-
chondrial cell death,” Science, vol. 305, no. 5684, pp. 626–629,
2004.
[63] S. A. Susin, N. Zamzami, and G. Kroemer, “Mitochondria
as regulators of apoptosis: doubt no more,” Biochimica et
Biophysica Acta, vol. 1366, no. 1-2, pp. 151–165, 1998.
[64] M. P. Murphy and R. A. J. Smith, “Drug delivery to mito-
chondria: the key to mitochondrial medicine,” Advanced Drug
Delivery Reviews, vol. 41, no. 2, pp. 235–250, 2000.
[65] I. Madar, H. Ravert, B. Nelkin et al., “Characterization of mem-
brane potential-dependent uptake of the novel PET tracer 18F-
fluorobenzyl triphenylphosphonium cation,” European Journal
of Nuclear Medicine and Molecular Imaging, vol. 34, no. 12, pp.
2057–2065, 2007.
[66] I. Madar, Y. Huang, H. Ravert et al., “Detection and quan-
tification of the evolution dynamics of apoptosis using the
PET voltage sensor18F-fluorobenzyl triphenyl phosphonium,”
Journal of Nuclear Medicine, vol. 50, no. 5, pp. 774–780, 2009.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
